# US 2024/0197664 A1 · Sirtuin or klotho activator or expression enhancer, nad+ increasing agent, and senolytic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197664 A1
- Document ID: US20240197664A1
- Status: Published application
- Kind: A1
- Application number: 18/555,106
- Filed: 2022-04-13
- Published: 2024-06-20
- Earliest claimed: 2021-04-13
- Assignees: Wakunaga Pharmaceutical Co., Ltd.
- Applicants: Wakunaga Pharmaceutical Co., Ltd.
- Inventors: Junichiro SUZUKI; Kayo FUJII; Miyuki TAKASHIMA; Satomi MIKI; Mitsuyasu USHIJIMA; Toshiaki MATSUTOMO
- Web page: https://patentgrep.com/patent/US20240197664A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 13/12: of the kidneys
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23L 33/175: Amino acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

A method for activating or enhancing expression of sirtuins or Klotho, including administering S-1-propenylcysteine or a salt thereof to an animal in need thereof. A method for increasing NAD+, including administering S-1-propenylcysteine or a salt thereof to an animal in need thereof. A method for suppressing senescent cells, including administering S-1-propenylcysteine or a salt thereof to an animal in need thereof.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A method for activating or enhancing expression of sirtuins or Klotho, comprising administering S-1-propenylcysteine or a salt thereof to an animal in need thereof.

### Claim 28

A method for increasing NAD+, comprising administering S-1-propenylcysteine or a salt thereof to an animal in need thereof.

### Claim 29

A method for suppressing senescent cells, comprising administering S-1-propenylcysteine or a salt thereof to an animal in need thereof.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the method is a method for removing senescent cells or a method for preventing or delaying a cellular senescence phenomenon.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the method suppresses senescence of non-cancer cells in the animal body.

### Claim 32 (depends on 29)

The method according to claim 29, wherein the method suppresses cells expressing p16, p21 or p53 genes.

### Claim 33 (depends on 27)

The method according to claim 27, wherein the method acts in one or more organs selected from the group consisting of kidney and brain.

### Claim 34 (depends on 28)

The method according to claim 28, wherein the method acts in one or more organs selected from the group consisting of kidney and brain.

### Claim 35 (depends on 29)

The method according to claim 29, wherein the method acts in one or more organs selected from the group consisting of kidney and brain.

### Claim 36 (depends on 27)

The method according to claim 27, wherein the method prevents, treats or ameliorates symptoms that result from low activity or low expression of sirtuins or Klotho, or symptoms that result from accumulation of senescent cells.

### Claim 37 (depends on 28)

The method according to claim 28, wherein the method prevents, treats or ameliorates symptoms that result from low activity or low expression of sirtuins or Klotho, or symptoms that result from accumulation of senescent cells.

### Claim 38 (depends on 29)

The method according to claim 29, wherein the method prevents, treats or ameliorates symptoms that result from low activity or low expression of sirtuins or Klotho, or symptoms that result from accumulation of senescent cells.

### Claim 39 (depends on 27)

The method according to claim 27, wherein the method prevents, treats or ameliorates symptoms or diseases selected from kidney injuries and cognitive/memory disorders.

### Claim 40 (depends on 28)

The method according to claim 28, wherein the method prevents, treats or ameliorates symptoms or diseases selected from kidney injuries and cognitive/memory disorders.

### Claim 41 (depends on 29)

The method according to claim 29, wherein the method prevents, treats or ameliorates symptoms or diseases selected from kidney injuries and cognitive/memory disorders.